Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 10,413 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $48.91, for a total value of $509,299.83. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Clay B. Siegall also recently made the following trade(s):
- On Wednesday, July 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The shares were sold at an average price of $51.98, for a total value of $541,787.54.
- On Monday, June 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The shares were sold at an average price of $65.21, for a total value of $679,683.83.
Shares of Seattle Genetics, Inc. (SGEN) traded down 0.15% on Friday, hitting $46.30. The stock had a trading volume of 645,370 shares. The firm’s 50-day moving average is $50.86 and its 200-day moving average is $60.76. The company’s market cap is $6.62 billion. Seattle Genetics, Inc. has a one year low of $42.58 and a one year high of $75.36.
Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.03. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The firm had revenue of $108.20 million for the quarter, compared to the consensus estimate of $105.92 million. During the same period in the previous year, the business earned ($0.23) earnings per share. The company’s revenue for the quarter was up 13.4% compared to the same quarter last year. On average, analysts expect that Seattle Genetics, Inc. will post ($1.70) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/20/seattle-genetics-inc-sgen-insider-clay-b-siegall-sells-10413-shares-updated.html.
A number of brokerages recently commented on SGEN. HC Wainwright upped their target price on Seattle Genetics from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Cann reiterated a “hold” rating on shares of Seattle Genetics in a research report on Thursday, April 27th. Zacks Investment Research upgraded Seattle Genetics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 2nd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Seattle Genetics in a research report on Saturday, June 3rd. Finally, Cowen and Company set a $61.00 target price on Seattle Genetics and gave the company a “hold” rating in a research report on Tuesday, June 6th. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $62.29.
Institutional investors have recently modified their holdings of the company. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Seattle Genetics during the first quarter valued at about $119,000. Tradewinds Capital Management LLC boosted its position in shares of Seattle Genetics by 2.3% in the first quarter. Tradewinds Capital Management LLC now owns 2,344 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 52 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Seattle Genetics by 562.5% in the first quarter. Daiwa Securities Group Inc. now owns 2,650 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 2,250 shares in the last quarter. First Manhattan Co. boosted its position in shares of Seattle Genetics by 31.3% in the second quarter. First Manhattan Co. now owns 3,150 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 750 shares in the last quarter. Finally, Capital Fund Management S.A. purchased a new position in shares of Seattle Genetics during the first quarter valued at about $208,000. 98.21% of the stock is owned by hedge funds and other institutional investors.
Seattle Genetics Company Profile
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.